Patents by Inventor Jong Ho Chun

Jong Ho Chun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulations of terameprocol and temozolomide and their use in stimulation of humoral immunity in tumors
    Patent number: 12171729
    Abstract: The present invention provides novel pharmaceutical formulations comprising derivatives of NDGA, including M4N (tetra-0-methyl nordihydroguaiaretic acid) and temozolomide and their use in the inhibition and treatment of neoplastic diseases, including glioblastoma multiforme, lung and other cancers.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: December 24, 2024
    Assignees: The Johns Hopkins University, Academia Sinica, National Yang Ming Chiao Tung University
    Inventors: Ru Chih C. Huang, Jong Ho Chun, Yu-Ling Lin, Yu-Chuan Liang, Kuang-Wen Liao, Tiffany Jackson, David Mold, Chien-Hsien Lai
  • FORMULATIONS OF TERAMEPROCOL AND TEMOZOLOMIDE AND THEIR USE IN STIMULATION OF HUMORAL IMMUNITY IN TUMORS
    Publication number: 20220409552
    Abstract: The present invention provides novel pharmaceutical formulations comprising derivatives of NDGA, including M4N (tetra-0-methyl nordihydroguaiaretic acid) and temozolomide and their use in the inhibition and treatment of neoplastic diseases, including glioblastoma multiforme, lung and other cancers.
    Type: Application
    Filed: November 25, 2020
    Publication date: December 29, 2022
    Inventors: Ru Chih C. Huang, Jong Ho Chun, Yu-Ling Lin, Yu-Chuan LIang, Kuang-Wen Liao, Tiffany Jackson, David Mold, Chien-Hsien Lai
  • Compositions comprising NDGA derivatives and sorafenib and their use in treatment of cancer
    Patent number: 9877978
    Abstract: The present invention provides pharmaceutical compositions comprising derivatives of NDGA, including M4N (tetra-O-methyl nordihydroguaiaretic acid) and sorafenib and their use in the inhibition and treatment of neoplastic diseases, such as liver cancer, colon cancer, breast cancer, brain cancers and ovarian cancers, for example, in a subject. Compositions comprising derivatives of NDGA, including M4N, sorafenib and additional therapeutic agents are also provided.
    Type: Grant
    Filed: February 4, 2013
    Date of Patent: January 30, 2018
    Assignee: The Johns Hopkins University
    Inventors: Ru Chih Huang, David Mold, Christopher Ruland, Yu-Chuan Liang, Jong Ho Chun
  • COMPOSITIONS COMPRISING NDGA DERIVATIVES AND SORAFENIB AND THEIR USE IN TREATMENT OF CANCER
    Publication number: 20150018302
    Abstract: The present invention provides pharmaceutical compositions comprising derivatives of NDGA, including M4N (tetra-O-methyl nordihydroguaiaretic acid) and sorafenib and their use in the inhibition and treatment of neoplastic diseases, such as liver cancer, colon cancer, breast cancer, brain cancers and ovarian cancers, for example, in a subject. Compositions comprising derivatives of NDGA, including M4N, sorafenib and additional therapeutic agents are also provided.
    Type: Application
    Filed: February 4, 2013
    Publication date: January 15, 2015
    Inventors: Ru Chih Huang, David Mold, Christopher Ruland, Yu-Chuan Liang, Jong Ho Chun